Oxysterols and methods of use thereof
US-10259840-B2 · Apr 16, 2019 · US
Neuroactive steroids, compositions, and uses thereof
US10759828B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10759828-B2 |
| Application number | US-201816114791-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 28, 2018 |
| Priority date | Sep 8, 2011 |
| Publication date | Sep 1, 2020 |
| Grant date | Sep 1, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v): and wherein L 1 , L 2 , L 3 , X 1 , X 2 , Y, R Z4 , R Z5 , R Z6 , n, R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , R 6a , R 6b , R 7a , R 7b , R 11a , R 11b , R 14 , R 17 , R 19 , R 20 , R 23a , R 23b , and R 24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.
First claim
Opening claim text (preview).
What is claimed is: 1. A process for preparing a compound having the formula comprising: contacting a compound having the formula with a reducing agent and CeCl 3 in methanol to provide a compound having the formula and contacting the compound INT H with a coupling agent and N-methylmorpholine in dichloromethane to produce the compound C_011_1, wherein the reducing agent is NaBH 4 and the coupling agent is methyl propiolate.
Assignees
Inventors
Classifications
- C07J9/00Primary
Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane · CPC title
- C07J41/00Primary
Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring · CPC title
Normal steroids containing one or more sulfur atoms not belonging to a hetero ring · CPC title
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title
- A61K31/57Primary
substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10759828B2 cover?
- Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v): and wherein L 1 , L 2 , L 3 , X 1 , X 2 , Y, R Z4 , R Z5 , R Z6 , n, R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , R 6a , R 6b , R 7a , R 7b , R 11a , R 11b , R 14 , R 17 , R 19 , R 20…
- Who is the assignee on this patent?
- Sage Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07J9/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).